top of page
  • Writer's pictureNammi Therapeutics

Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of MM

FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of multiple myeloma. QXL 138AM is a Masked Immunocytokine targeting a masked interferon alpha to the CD138 receptor on the surface of tumor cells.

June 13 2022 - QXL138AM Orphan Drug Designation in Multiple Myeloma
.pdf
Download PDF • 365KB

7 views0 comments

Recent Posts

See All

Comments


bottom of page